Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer
Shots:
- The companies will jointly develop vaccine candidates using Leidos’ PD-1 checkpoint inhibitors combined with GeoVax’s MVA-VLP vaccine platform
- GeoVax will design- construct- and characterize the developed product and further analysis will be done by Leidos
- GeoVax’s Modified Vaccinia Ankara (MVA) platform is used for developing in-vivo vaccines in the form of multimeric proteins or non-infectious VLPs (Virus-Like Particle)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
